Compare SHIM & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | LIXT |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 107.6M |
| IPO Year | 2023 | N/A |
| Metric | SHIM | LIXT |
|---|---|---|
| Price | $3.64 | $6.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 169.4K | ★ 364.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.58 | $0.68 |
| 52 Week High | $6.76 | $7.78 |
| Indicator | SHIM | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 55.62 |
| Support Level | $3.38 | $3.82 |
| Resistance Level | $4.10 | $7.50 |
| Average True Range (ATR) | 0.24 | 0.78 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 8.55 | 53.54 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.